A nanotherapeutic approach to selectively eliminate metastatic breast cancer cells by targeting cell surface GRP78

Area of Science:

• Nanomedicine
• Cancer Biology
• Pharmacology

Background:

• Glucose-regulated protein 78 (GRP78) is found on the cell surface of aggressive, metastatic breast cancer cells.
• GRP78 is a promising therapeutic target due to its selective expression in certain cancer cells.
• Targeting GRP78 could offer a strategy to inhibit cancer cell metastasis.

Purpose of the Study:

• To engineer peptide-targeted liposomal nanoparticles for selective delivery of doxorubicin prodrug.
• To target and inhibit the metastatic potential of GRP78-expressing breast cancer cells.
• To evaluate the efficacy of targeted nanoparticles in a preclinical lung metastasis model.

Main Methods:

• Development and optimization of a GRP78-binding peptide-functionalized nanoparticle (TNP^GRP78pep).
• In vitro assessment of cellular uptake and selectivity in breast cancer cell lines.
• In vivo evaluation of TNP^GRP78pep loaded with doxorubicin prodrug in a lung metastatic mouse model.

Main Results:

• TNP^GRP78pep demonstrated enhanced cellular uptake and selectivity in vitro.
• In vivo studies showed significant inhibition of breast cancer cell lung seeding.
• The targeted nanoparticle formulation achieved efficacy comparable to negative control groups.

Conclusions:

• Specific targeting of surface GRP78-expressing breast cancer cells effectively inhibits lung metastasis.
• The study validates the significance of GRP78 as a target for inhibiting breast cancer metastasis.
• Peptide-targeted liposomal nanoparticles represent a promising strategy for metastatic breast cancer treatment.